Lifitegrast

Generic Name: Lifitegrast

Brand Names: Xiidra

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₂₄Cl_₂N_₂O_₇S

CAS Number: 1025967-78-5

Unique Ingredient Identifier: 038E5L962W

Background: Lifitegrast is a FDA approved drug for the treatment of keratoconjunctivitis sicca (dry eye syndrome). It is a tetrahydroisoquinoline derivative and lymphocyte function-associated antigen-1 ( LFA-1) antagonist that was discovered through the rational design process. The ophthalmic solution was approved in July, 2016 under the trade name Xiidra. It has shown to protect the corneal surface and alleviate the symptoms of dry eye syndrome with fast onset of action and well tolerated profile in both local and systemic setting .

Indication: 适用于治疗干眼病（DED）的症状和体征。

Associated Conditions: Dry Eye Syndrome (DES)

Clinical Trials

The Effect of Xiidra on Comfort and Dryness in Symptomatic Contact Lens Wearers

Phase 4

Completed

Conditions: Dry Eye

Interventions: Drug: Xiidra

First Posted Date: 2020-03-05

Last Posted Date: 2025-05-04

Lead Sponsor: University of Waterloo

Target Recruit Count: 45

Registration Number: NCT04297618

Locations: 🇨🇦
Centre for Ocular Research & Education, Waterloo, Ontario, Canada

Clinical Efficacy of Two Topical Dry Eye Drops for Central Corneal Stain Clearing Over 90 Days

Phase 4

Recruiting

Conditions: Dry Eye

Interventions: Drug: nanomicellular cyclosporine 0.09%
Drug: Lifitegrast

First Posted Date: 2019-11-21

Last Posted Date: 2022-10-20

Lead Sponsor: Toyos Clinic

Target Recruit Count: 100

Registration Number: NCT04172961

Locations: 🇺🇸
Toyos Clinic, Nashville, Tennessee, United States

Ocular Inflammation in Cataract Patients and Response to Treatment With Xiidra

Phase 4

Withdrawn

Conditions: Dry Eye

Interventions: Drug: Lifitegrast 5% Ophthalmic Solution

First Posted Date: 2019-10-09

Last Posted Date: 2023-07-27

Lead Sponsor: Bucci Laser Vision Institute

Registration Number: NCT04120987

Locations: 🇺🇸
Bucci Laser Vision, Wilkes-Barre, Pennsylvania, United States

A Study of the Drugs AGN-242428 and AGN-231868 in Participants With Dry Eye Disease

Phase 1

Completed

Conditions: Dry Eye Syndrome
Dry Eye Disease

Interventions: Drug: AGN-242428
Other: AGN-242428 Vehicle
Drug: AGN-231868
Other: AGN-231868 Vehicle
Drug: Lifitegrast 5% Ophthalmic Solution

First Posted Date: 2019-07-24

Last Posted Date: 2025-05-20

Lead Sponsor: AbbVie

Target Recruit Count: 292

Registration Number: NCT04030962

Locations: 🇺🇸
Duplicate_Alpine Research Organization, Inc. /ID# 240508, Clinton, Utah, United States
🇺🇸
Cornea and Cataract Consultants of Arizona /ID# 232769, Phoenix, Arizona, United States
🇺🇸
The Eye Research Foundation /ID# 232696, Newport Beach, California, United States

and more 8 locations